ABSTRACT
Background There is an urgent need for tools allowing the early prognosis and subsequent monitoring of individuals with heterogeneous COVID-19 disease trajectories. Pre-existing cardiovascular (CV) disease is a leading risk factor for COVID-19 susceptibility and poor outcomes, and cardiac involvement is prevalent in COVID-19 patients both during the acute phase as well as in convalescence. The utility of traditional CV risk biomarkers in mild COVID-19 disease or across disease course is poorly understood. We sought to determine if a previously validated 27-protein predictor of CV outcomes served a purpose in COVID-19.
Methods The 27-protein test of residual CV (RCV) risk was applied without modification to n=860 plasma samples from hospitalized and non-hospitalized SARS-CoV-2 infected individuals at disease presentation from three independent cohorts to predict COVID-19 severity and mortality. The same test was applied to an additional n=991 longitudinal samples to assess sensitivity to change in CV risk throughout the course of infection into convalescence.
Results In each independent cohort, RCV predictions were significantly related to maximal subsequent COVID-19 severity and to mortality. At the baseline blood draw, the mean protein-predicted likelihood of an event in subjects who died during the study period ranged from 88-99% while it ranged from 8-36% in subjects who were not admitted to hospital. Additionally, the test outperformed existing risk predictors based on commonly used laboratory chemistry values or presence of comorbidities. Application of the RCV test to sequential samples showed dramatic increases in risk during the first few days of infection followed by risk reduction in the survivors; a period of catastrophically high cardiovascular risk (above 50%) typically lasted 8-12 days and had not resolved to normal levels in most people within that timescale.
Conclusions The finding that a 27-protein candidate CV surrogate endpoint developed in multi-morbid patients prior to the pandemic is both prognostic and acutely sensitive to the adverse effects of COVID-19 suggests that this disease activates the same biologic risk-related mechanisms. The test may be useful for monitoring recovery and drug response.
Competing Interest Statement
CP, YH, MAH, and SAW are employees of SomaLogic Inc. RH and LLJ are employees and stockholders of Novartis.
Funding Statement
This study was funded in part by Novartis Institutes for BioMedical Research. This work was supported, in part, by the Bill & Melinda Gates Foundation [OPPID]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. Additional funding for the ISB cohort, ATM, and JRH were supported by Biomedical Advanced Research and Development Authority under Contract HHSO10201600031C administered by Merck and Co.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research conducted in this report were done so under studies reviewed and approved by the appropriate Institutional Review Board for each individual study as follows: Cohort 1, Mt Sinai School of Medicine. This study was reviewed and approved by the Institutional Review Board of the Human Research Protection Program at the Icahn School of Medicine at Mount Sinai. Cohort 2, Massachusetts General Hospital. This study was approved by the Partners Human Research Committee Institutional Review Board. Cohort 3, Institute for Systems Biology. This study was approved by the Providence Institutional Review Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Sources of funding This study was funded in part by Novartis Institutes for BioMedical Research. This work was supported, in part, by the Bill & Melinda Gates Foundation [OPPID]. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. Additional funding for the ISB cohort, ATM, and JRH were supported by Biomedical Advanced Research and Development Authority under Contract HHSO10201600031C administered by Merck and Co.
Disclosures CP, YH, MAH, and SAW are employees of SomaLogic Inc. RH and LLJ are employees and stockholders of Novartis.
Data Availability
The datasets analyzed during the current study are not publicly available due to United States Federal Health Insurance Portability and Accountability Act (HIPAA) compliance.
